Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 2Phase NA 1Phase 3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 2Recurrence 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 388Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Has results × WW Domain-Containing Oxidoreductase × Clear all
NCT00511238 2017-08-31

Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma

Amgen

Phase 2 Completed
312 enrolled 16 charts
Plasma cell

Multiple Myeloma, Recurrence

NCT00530816 2017-05-02

Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma

Amgen

Phase 2 Completed
164 enrolled 16 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡